20 hours ago
1
sanjeri/E+ via Getty Images
Madrigal Pharmaceuticals (NASDAQ:MDGL) said it has signed a global licensing deal with CSPC Pharmaceutical for SYH2086, a new oral GLP-1 receptor agonist being developed as an obesity treatment.
As part of the agreement, CSPC will allow Madrigal to exclusively develop, manufacture, and market
English (US) ·